Immune mechanisms involved in cardiovascular complications of chronic kidney disease

Blood Purification

Volumn 29, Issue 2, 2010, Pages 114-120

  Stinghen, Andréa E M ^a,b   Bucharles, Sergio ^a   Riella, Miguel C ^a   Pecoits Filho, R ^a,c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c Centro de Ciências Biológicas e Da Saúde   (Brazil)

Author keywords

Atherosclerosis; Cardiovascular disease; Chronic kidney disease, inflammation; Myocardiopathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG MECHANISM; HEART DISEASE; HEMODYNAMICS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INTERLEUKIN-6; KIDNEY DISEASES; MEMBRANES, ARTIFICIAL; MICE; PERIODONTITIS; RENAL DIALYSIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 77749306557     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245636     Document Type: Review

References (50)

1. Hauser AB, Stinghen AE, Kato S, Bucharles S, Aita C, Yuzawa Y, et al: Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 2008; 28(suppl 3):S183-S187.
2. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, et al: Review on uraemic toxins. III. Recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrol Dial Transplant 2007; 22: 3381-3390.
3. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526-1533.
4. Li AC, Glass CK: The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002; 8: 1235-1242.
5. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
6. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
7. Bro S, Moeller F, Andersen CB, Olgaard K, Nielsen LB: Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J Am Soc Nephrol 2004; 15: 1495-1503.
8. Gonzalez MA, Selwyn AP: Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003; 115(suppl 8A):99S-106S.
9. Segal MS, Baylis C, Johnson RJ: Endothelial health and diversity in the kidney. J Am Soc Nephrol 2006; 17: 323-324.
10. Diaz-Buxo JA, Woods HF: Protecting the endothelium: a new focus for management of chronic kidney disease. Hemodial Int 2006; 10: 42-48.
11. Bhagat K, Vallance P: Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.
12. Zwaka PT, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages. Circulation 2001; 103: 1194-1202.
13. Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al: Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 2009; 111:c117-c126.
14. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521.
15. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: Plasma concentrations of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
16. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O: Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15: 1624-1630.
17. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290.
18. London GM: Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 2002; 17(suppl 1):29-36.
19. Ritz E: Left ventricular hypertrophy in renal disease: beyond preload and afterload. Kidney Int 2009; 75: 771-773.
20. Gross ML, Ritz E: Hypertrophy and fibrosis in the cardiomyopathy of uremia - beyond coronary heart disease. Semin Dial 2008; 21: 308-318.
21. Tyralla K, Amann K: Morphology of the heart and arteries in renal failure. Kidney Int Suppl 2003; 84:S80-S83.
22. Schunkert H, Hense HW: Molecular genetics of cardiovascular diseases (in German). Dtsch Med Wochenschr 1995; 120: 533-539.
23. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, et al: Left ventricular mass monitoring in the followup of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-1498.
24. Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B, et al: Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000; 36: 864-870.
25. Santoro A, Mancini E, Basile C, Amoroso L, Di Giulio S, Usberti M, et al: Blood volume controlled hemodialysis in hypotensionprone patients: a randomized, multicenter controlled trial. Kidney Int 2002; 62: 1034-1045.
26. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-1206.
27. Lopez D, Rodriguez-Sinovas A, Agullo L, Inserte J, Cabestrero A, Garcia-Dorado D: Acidic reoxygenation protects against endothelial dysfunction in rat aortic rings submitted to simulated ischemia. Am J Physiol Heart Circ Physiol 2008; 295:H2409-H2416.
28. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, et al: Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999; 22: 811-813.
29. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838-1842.
30. Goncalves S, Pecoits-Filho R, Perreto S, Barberato SH, Stinghen AE, Lima EG, et al: Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006; 21: 2788-2794.
31. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ: Vitamin D insufficiency and deficiency in chronic kidney disease: a single center observational study. Am J Nephrol 2004; 24: 503-510.
32. Park MS, Lee HB: AGE accumulation in peritoneal membrane and cavity during peritoneal dialysis and its effect on peritoneal structure and function. Perit Dial Int 1999; 19(suppl 2):S53-S57.
33. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, et al: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
34. Panichi V, Tetta C, Rindi P, Palla R, Lonnemann G: Plasma C-reactive protein is linked to backfiltration associated interleukin-6 production. Asaio J 1998; 44:M415-M417.
35. Valdivielso JM, Ayus JC: Role of vitamin D receptor activators on cardiovascular risk. Kidney Int Suppl 2008; 111:S44-S49.
36. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
37. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
38. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, et al: Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-1324.
39. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, et al: Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 2006; 21: 2507-2512.
40. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, et al: Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
41. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002; 61: 297-304.
42. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
43. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213-1218.
44. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107: 992-995.
45. Andress DL: Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.
46. Lee P, Peng H, Gelbart T, Wang L, Beutler E: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005; 102: 1906-1910.
47. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB, et al: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008; 3: 431-436.
48. Perianayagam MC, Jaber BL: Endotoxinbinding affinity of sevelamer hydrochloride. Am J Nephrol 2008; 28: 802-807.
49. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825.
50. Stinghen AEM, Goncalves SM, Bucharles S, Branco FS, Gruber B, Hauser A, Pecoits-Filho R: Sevelamer decreases systemic inflammation through its endotoxin binding effects. Blood Purif, submitted.